Speakers:  Ferhan Qureshi, Vice President Biomarker Product Development at Octave Bioscience

Original Broadcast date:  April 01 2021

The current standard of care for Multiple Sclerosis patients relies heavily on assessments that are subjective, qualitative and inadequate. Octave Bioscience has developed an integrated Care Platform that consists of several tools to improve measurement capabilities in MS including: (1) Enhanced MRI readings and interpretation, (2) Mobile applications, sensors, and wearables to track shifts and changes in symptoms and (3) A custom assay panel performed using the Olink Platform to quantitatively assess the level of disease activity in blood samples.

The development of this panel involved biomarker discovery efforts for which over 1000 proteins were screened in several deeply phenotyped studies and associated with clinical and radiographic endpoints. A dynamic and iterative process that balanced statistical, analytical, and biological factors was then used to select proteins for inclusion in the custom panel. The 21-plex panel has been manufactured and analytically validated in preparation for a forthcoming clinical validation in independent cohorts. The subject of this webinar was to review the research, development and validation of the custom assay panel.

If you have any questions about Olink, please contact us at info@olink.com.